WHO 1973 Grade 3 and Infiltrative Growth Pattern Proved, Aberrant E-cadherin Expression Tends to Be of Predictive Value for Progression in a Series of Stage T1 High-grade Bladder Cancer After Organ-sparing Approach

Overview

Journal Int Urol Nephrol

Publisher Springer

Specialty Nephrology

Date 2016 Dec 31

PMID 28035618

Citations 8

Authors

Wolfgang Otto

Johannes Breyer

Sonja Herdegen

Fabian Eder

Simone Bertz

Matthias May

Roman Mayr

Eva M Lausenmeyer

Stefan Denzinger

Bas W G van Rhijn

Maximilian Burger

Arndt Hartmann

Affiliations

Soon will be listed here.

Abstract

Purpose: Stage pT1 urothelial bladder cancer (UBC) is characterized as a challenging subentity of urothelial carcinoma with an unforeseeable clinical course. In addition to more or less established clinical and histopathological features, we evaluated the role of epithelial-mesenchymal transition (EMT) marker E-cadherin, shown to be of prognostic value in muscle-invasive disease, regarding the prognosis of stage pT1 high-grade (hg) UBC.

Methods: Tissue of 226 stage pT1 hg UBC patients from transurethral resection could be immunostained for E-cadherin. Kaplan-Meier analysis and univariate and multivariate Cox regression analyses regarding progression-free (PFS) and cancer-specific survival (CSS) were performed.

Results: Aberrant expression of E-cadherin was recognized in 74% of patients. Kaplan-Meier analysis showed that aberrant E-cadherin expression was associated with worse 10-year PFS (62 vs. 90%, p = 0.045). In univariate analysis, aberrant E-cadherin staining, associated carcinoma in situ, grading 3 after WHO classification 1973 and infiltrative growth pattern at the invasion front were the statistically significant predictive factors for worse PFS, only infiltrative growth pattern for CSS. With regard to progression, grading 3 after WHO classification of 1973 (HR 6.49; CI 1.54-27.28, p = 0.011) and infiltrative tumor invasion pattern (HR 2.06; CI 1.10-3.86, p = 0.024) revealed as independent factors for PFS, and there was a trend also for E-cadherin expression (HR 0.45; CI 0.19-1.06; p = 0.068). Regarding CSS, infiltrative tumor growth pattern (HR 3.79; CI 1.67-8.60, p = 0.001) was the only statistically significantly independent predictive factor in multivariate Cox regression analysis.

Conclusions: Beside invasion growth pattern and WHO grading 1973 that achieved to be independent prognostic factors, there was a trend for the parameter E-cadherin expression to be of predictive value for PFS in stage pT1 hg urothelial bladder carcinoma after organ-sparing approach. Further studies on genetic level are warranted to define the distinct role of EMT in early-invasive UBC.

Citing Articles

Relevance of the Immunohistochemical Expression of p53 and E-cadherin in the Grading of Urothelial Carcinoma: A Single-Center Cross-Sectional Observational Study.

Singh M, Sahay R, Tiwari K, Prakash S Cureus. 2024; 16(10):e72132.

PMID: 39575056 PMC: 11581451. DOI: 10.7759/cureus.72132.

Nomogram for the Pathological Complete Response After Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients.

Shan L, Xu H, Piao C, Liu Z, Xie S Ann Surg Oncol. 2024; 32(1):589-597.

PMID: 39467974 DOI: 10.1245/s10434-024-16429-9.

Comparative analysis of recurrence rates between intravesical gemcitabine and bacillus Calmette-Guérin induction therapy following transurethral resection of bladder tumors in patients with intermediate- and high-risk bladder cancer: A retrospective....

Choi J, Kim K, Kim H, Yoon H, Kim J, Kim J Investig Clin Urol. 2024; 65(3):248-255.

PMID: 38714515 PMC: 11076792. DOI: 10.4111/icu.20230313.

The role of cell adhesion molecules in the progression of bladder urothelial carcinomas.

Sandulescu A, Stepan A, Margaritescu C, Enachescu V, Mitroi G, Simionescu C Rom J Morphol Embryol. 2022; 63(1):145-151.

PMID: 36074678 PMC: 9593113. DOI: 10.47162/RJME.63.1.15.

Non-muscle invasive bladder cancer biomarkers beyond morphology.

De Carlo C, Valeri M, Corbitt D, Cieri M, Colombo P Front Oncol. 2022; 12:947446.

PMID: 35992775 PMC: 9382689. DOI: 10.3389/fonc.2022.947446.

References

Shahin O, Thalmann G, Rentsch C, Mazzucchelli L, Studer U . A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol. 2002; 169(1):96-100; discussion 100. DOI: 10.1016/S0022-5347(05)64044-X. View

Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T . Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer. 2005; 5(9):744-9. DOI: 10.1038/nrc1694. View

Jang T, Cha W, Lee K . Reciprocal correlation between the expression of cyclooxygenase-2 and E-cadherin in human bladder transitional cell carcinomas. Virchows Arch. 2010; 457(3):319-28. DOI: 10.1007/s00428-010-0943-3. View

Denzinger S, Burger M, Fritsche H, Bertz S, Hofstadter F, Wieland W . Prognostic value of histopathological tumour growth patterns at the invasion front of T1G3 urothelial carcinoma of the bladder. Scand J Urol Nephrol. 2009; 43(4):282-7. DOI: 10.1080/00365590902854354. View

Baum B, Settleman J, Quinlan M . Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol. 2008; 19(3):294-308. DOI: 10.1016/j.semcdb.2008.02.001. View

Otto W, Denzinger S, Fritsche H, Burger M, Wieland W, Hofstadter F . The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer. BJU Int. 2010; 107(3):404-8. DOI: 10.1111/j.1464-410X.2010.09515.x. View

Spaderna S, Schmalhofer O, Hlubek F, Berx G, Eger A, Merkel S . A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology. 2006; 131(3):830-40. DOI: 10.1053/j.gastro.2006.06.016. View

Brake M, Loertzer H, Horsch R, Keller H . Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. J Urol. 2000; 163(6):1697-701. View

Byrne R, Shariat S, Brown R, Kattan M, Morton RA J, Wheeler T . E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol. 2001; 165(5):1473-9. View

10.

Bertz S, Denzinger S, Otto W, Wieland W, Stoehr R, Hofstaedter F . Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bladder cancer-evaluation of a large hospital-based single-centre series. Histopathology. 2011; 59(4):722-32. DOI: 10.1111/j.1365-2559.2011.03989.x. View

11.

Muramaki M, Miyake H, Terakawa T, Kumano M, Sakai I, Fujisawa M . Expression profile of E-cadherin and N-cadherin in non-muscle-invasive bladder cancer as a novel predictor of intravesical recurrence following transurethral resection. Urol Oncol. 2010; 30(2):161-6. DOI: 10.1016/j.urolonc.2010.01.005. View

12.

San Miguel Fraile P, Gomez de Maria C, Donis Quintairos L, Carrera Vazquez A, Iglesias Martinez P, Barreiro Barbosa M . [Expresion of E-cadherin and catenins in urothelial carcinomas]. Actas Urol Esp. 2007; 31(4):355-60. DOI: 10.1016/s0210-4806(07)73649-5. View

13.

Hurle R, Losa A, Manzetti A, Lembo A . Intravesical bacille Calmette-Guérin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up. Urology. 1999; 54(2):258-63. DOI: 10.1016/s0090-4295(99)00116-8. View

14.

Moyano Calvo J, Blanco Palenciano E, Beato Moreno A, Gutierrez Gonzalez M, Perez-Lanzac Lorca A, Samaniego Torres A . [Prognostic value of E-cadherina, beta catenin, Ki-67 antigen and p53 protein in the superficial bladder tumors]. Actas Urol Esp. 2006; 30(9):871-8. DOI: 10.1016/s0210-4806(06)73553-7. View

15.

Baumgart E, Cohen M, Silva Neto B, Jacobs M, Wotkowicz C, Rieger-Christ K . Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors. Clin Cancer Res. 2007; 13(6):1685-94. DOI: 10.1158/1078-0432.CCR-06-2330. View

16.

Lebret T, Gaudez F, Herve J, Barre P, Lugagne P, Botto H . Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: recurrence, progression and success. Eur Urol. 1998; 34(1):67-72. DOI: 10.1159/000019664. View

17.

Clairotte A, Lascombe I, Fauconnet S, Mauny F, Felix S, Algros M . Expression of E-cadherin and alpha-, beta-, gamma-catenins in patients with bladder cancer: identification of gamma-catenin as a new prognostic marker of neoplastic progression in T1 superficial urothelial tumors. Am J Clin Pathol. 2006; 125(1):119-26. View

18.

Orsola A, Trias I, Raventos C, Espanol I, Cecchini L, Bucar S . Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur Urol. 2005; 48(2):231-8. DOI: 10.1016/j.eururo.2005.04.013. View

19.

Tarin D, Thompson E, Newgreen D . The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res. 2005; 65(14):5996-6000. DOI: 10.1158/0008-5472.CAN-05-0699. View

20.

Bryan R, Atherfold P, Yeo Y, Jones L, Harrison R, Wallace D . Cadherin switching dictates the biology of transitional cell carcinoma of the bladder: ex vivo and in vitro studies. J Pathol. 2008; 215(2):184-94. DOI: 10.1002/path.2346. View